Zhaopei Liu
Overview
Explore the profile of Zhaopei Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
461
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gender disparities in clinical outcomes of urothelial carcinoma linked to X chromosome gene mutation
Liu Z, Jin K, Xu Z, Xu J, Su X, Li B, et al.
BMJ Oncol
. 2025 Jan;
2(1):e000199.
PMID: 39886491
Objective: , a representative tumour suppressor gene with sex bias, is frequently altered in urothelial carcinoma (UC). The specific impacts of mutations on gender-based clinical outcomes in UC remain poorly...
2.
Jin K, Ding Y, Xu J, Liu Z, Zeng H, Su X, et al.
J Immunother Cancer
. 2025 Jan;
13(1.
PMID: 39762080
Background: The E3 ubiquitin ligase murine double minute 2 (MDM2) binds the p53 transcriptional activation domain and acts as a potent inhibitor of pathway, one of the three most crucial...
3.
Lu X, Ge L, Liu Z, Zhu Y, Ye D, Chang Y
Front Oncol
. 2024 Nov;
14:1498579.
PMID: 39588301
Background: Increasing evidence suggests that the CXC chemokine receptor 6 (CXCR6) is involved in tumor progression and the regulation of tumor immunity. However, its role in muscle-invasive bladder cancer (MIBC)...
4.
Li B, Jin K, Liu Z, Su X, Xu Z, Liu G, et al.
J Immunother
. 2024 May;
48(1):18-26.
PMID: 38800996
RAD51, a key recombinase that catalyzes homologous recombination (HR), is commonly overexpressed in multiple cancers. It is curial for DNA damage repair (DDR) to maintain genomic integrity which could further...
5.
Liu G, Jin K, Liu Z, Su X, Xu Z, Li B, et al.
Cancer Med
. 2024 Mar;
13(4):e6962.
PMID: 38457207
Background: Though programmed cell death-ligand 1 (PD-L1) has been used in predicting the efficacy of immune checkpoint blockade (ICB), it is insufficient as a single biomarker. As a key effector...
6.
Li B, Jin K, Liu Z, Su X, Xu Z, Liu G, et al.
Cancer Immunol Immunother
. 2024 Mar;
73(4):66.
PMID: 38430246
Background: Luminal and Basal are the primary intrinsic subtypes of muscle-invasive bladder cancer (MIBC). The presence of CD8 T cells infiltration holds significant immunological relevance, potentially influencing the efficacy of...
7.
Liu G, Jin K, Liu Z, Su X, Xu Z, Li B, et al.
Cancer Sci
. 2024 Feb;
115(4):1306-1316.
PMID: 38402640
Muscle-invasive bladder cancer (MIBC) is a disease characterized by molecular and clinical heterogeneity, posing challenges in selecting the most appropriate treatment in clinical settings. Considering the significant role of CD4...
8.
Jin K, Xu J, Su X, Xu Z, Li B, Liu G, et al.
J Pathol
. 2024 Feb;
263(2):139-149.
PMID: 38380548
TP53 mutation is one of the most common genetic alterations in urothelial carcinoma (UrCa), and heterogeneity of TP53 mutants leads to heterogeneous clinical outcomes. This study aimed to investigate the...
9.
Su X, Jin K, Guo Q, Xu Z, Liu Z, Zeng H, et al.
Br J Cancer
. 2024 Jan;
130(5):852-860.
PMID: 38212482
Background: Cyclin-dependent kinase 6 (CDK6) was proved to be an important regulator in the progression of cell cycle and has been a promising therapeutic target in cancer treatment. However, the...
10.
Shao F, Jin K, Li B, Liu Z, Zeng H, Wang Y, et al.
Urol Oncol
. 2023 Aug;
41(10):433.e9-433.e18.
PMID: 37625906
Background: Muscle-invasive bladder cancer (MIBC) patients have benefitted greatly from immune checkpoint blockade (ICB) therapy. However, there is a pressing need to identify factors underlying the heterogeneity of clinical responses...